VINCRISTINE sulfate, 1mg/ml, 1ml, vial
Valid Article
VINCRISTINE
- In the WHO list of Essential Medicines 2023 (Complementary List)
Therapeutic Action
Antimitotic cytotoxic medicine
Indications
Treatment of Kaposi's sarcoma in HIV patients, in combination with bleomycine
Instructions for use
Must only be given as IV infusion in 0.9% NaCl or 5% dextrose.
Ensure that the IV catheter is properly positioned in the vein before injection of vincristine. Leakage into surrounding tissue during administration may cause severe pain and severe local tissue irritation.
Purge the vein after administration of vincristine to prevent vessel irritation.
The two presentations (1 or 2 ml) are interchangeable according to availability when ordering.
Bleomycin, another cytotoxic medicine, should be systematically ordered together with vincristine as they have to be used in combination.
Precautions for Use
Administer by IV route only, fatal if given by other routes.
Contraindicated during pregnancy and breastfeeding.
- Dangerous substance for the staff handling it.
- Cytotoxic drugs should not be handled or administered by pregnant staff members.
- It is mandatory to train the staff and to follow the Standard Precautions during preparation, reconstitution, dispensation, stock management and disposal: wear gloves, gown with long sleeves, protective glasses, respirator, etc.
(See introduction: Cytotoxic drugs in the MSF Supply Chain)
Storage
- Keep refrigerated between 2ºC and 8ºC - Protect from sunlight
- Do not freeze.
- After dilution, use the solution immediately.